GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Getinge AB (OTCPK:GNGBF) » Definitions » EV-to-EBIT

Getinge AB (Getinge AB) EV-to-EBIT : 15.15 (As of Jun. 15, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Getinge AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Getinge AB's Enterprise Value is $5,222 Mil. Getinge AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $345 Mil. Therefore, Getinge AB's EV-to-EBIT for today is 15.15.

The historical rank and industry rank for Getinge AB's EV-to-EBIT or its related term are showing as below:

GNGBF' s EV-to-EBIT Range Over the Past 10 Years
Min: -193.77   Med: 18.74   Max: 258.98
Current: 15.34

During the past 13 years, the highest EV-to-EBIT of Getinge AB was 258.98. The lowest was -193.77. And the median was 18.74.

GNGBF's EV-to-EBIT is ranked better than
61.33% of 450 companies
in the Medical Devices & Instruments industry
Industry Median: 19.47 vs GNGBF: 15.34

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Getinge AB's Enterprise Value for the quarter that ended in Mar. 2024 was $5,829 Mil. Getinge AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $345 Mil. Getinge AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 5.91%.


Getinge AB EV-to-EBIT Historical Data

The historical data trend for Getinge AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Getinge AB EV-to-EBIT Chart

Getinge AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.37 12.02 24.95 16.18 17.49

Getinge AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.53 16.29 14.94 17.49 17.39

Competitive Comparison of Getinge AB's EV-to-EBIT

For the Medical Devices subindustry, Getinge AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Getinge AB's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Getinge AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Getinge AB's EV-to-EBIT falls into.



Getinge AB EV-to-EBIT Calculation

Getinge AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5221.859/344.65
=15.15

Getinge AB's current Enterprise Value is $5,222 Mil.
Getinge AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $345 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Getinge AB  (OTCPK:GNGBF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Getinge AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=344.65/5828.8392
=5.91 %

Getinge AB's Enterprise Value for the quarter that ended in Mar. 2024 was $5,829 Mil.
Getinge AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $345 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Getinge AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Getinge AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Getinge AB (Getinge AB) Business Description

Address
Lindholmspiren 7A, P.O. Box 8861, Gothenburg, SWE, SE-417 56
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (54% of revenue), surgical workflows (32%), and life sciences (14%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales (U.S. 33% of sales), Asia-Pacific 25%, and Europe, Middle East, and Africa the remaining 30%.